According to a new report, published by KBV research, The Global Postpartum Depression Drugs Market size is expected to reach $1.7 billion by 2031, rising at a market growth of 9.4% CAGR during the forecast period.
The Pharmacotherapy segment generated the highest revenue the Global Postpartum Depression Drugs Market by Treatment in 2023; thereby, achieving a market value of $875.4 million by 2031. Pharmacotherapy, encompassing antidepressants and anti-anxiety medications, is widely acknowledged for its effectiveness in treating moderate to severe postpartum depression.
The Oral segment is registering a CAGR of 9.1 % during the forecast period. Oral medications are preferred because they are easy to administer and can be taken at home, providing convenience for new mothers experiencing postpartum depression (PPD). This method of administration reduces the need for invasive procedures and allows for self-management of medication schedules.
The Hospital Pharmacy segment led the Global Postpartum Depression Drugs Market by Distribution Channel in 2023; thereby, achieving a market value of $750.7 million by 2031. Postpartum depression can manifest in severe forms that necessitate hospitalization for intensive treatment and monitoring. Hospitals stock a wide range of medications, including antidepressants and mood stabilizers, to manage acute symptoms effectively.
The Postpartum Anxiety segment is growing at a CAGR of 8.5 % during the forecast period. Postpartum anxiety disorders, including generalized anxiety disorder and specific phobias related to motherhood, are increasingly recognized as common mental health issues affecting new mothers. Studies indicate that anxiety disorders can co-occur with or manifest separately from postpartum depression, underscoring their prevalence and impact.
Full Report: https://www.kbvresearch.com/postpartum-depression-drugs-market/
The North America region dominated the Global Postpartum Depression Drugs Market by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $622.2 million by 2031. The Europe region is anticipated to grow at a CAGR of 9.2% during (2024 - 2031). Additionally, The Asia Pacific region would witness a CAGR of 10% during (2024 - 2031).
By Treatment
By Route of Administration
By Distribution Channel
By Type
Unique Offerings 
